ACUR · As filed with the SEC
Acura Pharmaceuticals balance sheet, by quarter
The statement as Acura Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | Q4 2021 Dec 31, 2021 | Q3 2021 Sep 30, 2021 | Q2 2021 Jun 30, 2021 | Q1 2021 Mar 31, 2021 | Q4 2020 Dec 31, 2020 | Q3 2020 Sep 30, 2020 | Q2 2020 Jun 30, 2020 | Q1 2020 Mar 31, 2020 |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Cash | 65,000 | 89,000 | 167,000 | 361,000 | 413,000 | 493,000 | 1,038,000 | 1,210,000 |
| Royalty receivable | 30,000 | 67,000 | 0 | 30,000 | 30,000 | 6,000 | 30,000 | 30,000 |
| Collaboration receivable from related party | 78,000 | 73,000 | 114,000 | 104,000 | 197,000 | 115,000 | 49,000 | 5,000 |
| License fees receivable from related party | 50,000 | 400,000 | 1,000,000 | 800,000 | 400,000 | 800,000 | 700,000 | — |
| Prepaid expenses and other current assets | 149,000 | 216,000 | 28,000 | 84,000 | 139,000 | 209,000 | 55,000 | 75,000 |
| Income tax receivable | — | — | — | — | — | 0 | 68,000 | 68,000 |
| Total current assets | 372,000 | 845,000 | 1,309,000 | 1,379,000 | 1,179,000 | 1,623,000 | 1,940,000 | 1,388,000 |
| Income tax receivable | — | — | — | — | — | 0 | 0 | — |
| Finance lease right of use | 50,000 | 59,000 | 66,000 | — | — | — | — | — |
| Property, plant and equipment, net | 438,000 | 449,000 | 461,000 | 473,000 | 484,000 | 498,000 | 511,000 | 525,000 |
| Intangible asset, net | 0 | 53,000 | 60,000 | 66,000 | 73,000 | 78,000 | 85,000 | 91,000 |
| Total assets | 860,000 | 1,406,000 | 1,896,000 | 1,918,000 | 1,736,000 | 2,199,000 | 2,536,000 | 2,004,000 |
| Liabilities: | ||||||||
| Accounts payable | 192,000 | 135,000 | 205,000 | 65,000 | 31,000 | 284,000 | 141,000 | 108,000 |
| Accrued expenses | 238,000 | 771,000 | 673,000 | 664,000 | 631,000 | 721,000 | 645,000 | 631,000 |
| Finance lease liability - current | 33,000 | 33,000 | 33,000 | — | — | — | — | — |
| Loans under CARES Act | 0 | 0 | 164,000 | 164,000 | 164,000 | 164,000 | 120,000 | — |
| Other current liabilities | 52,000 | 41,000 | 35,000 | 0 | 18,000 | 16,000 | 15,000 | 6,000 |
| Sales returns liability | — | — | — | — | 0 | 0 | 0 | 223,000 |
| Accrued interest to related party | 0 | 0 | 0 | 791,000 | 678,000 | — | 454,000 | 341,000 |
| Convertible debt to related party, net of discounts | 0 | 0 | 0 | 6,000,000 | 6,000,000 | — | 6,000,000 | 6,000,000 |
| Total current liabilities | 515,000 | 980,000 | 1,110,000 | 7,684,000 | 7,522,000 | 1,185,000 | 7,375,000 | 7,309,000 |
| Convertible debt to related party, net of discounts (Note 7) | — | — | — | — | — | 6,000,000 | 0 | 0 |
| Accrued interest to related party (Note 7) | — | — | — | — | — | 566,000 | 0 | 0 |
| Finance lease liability - noncurrent | 17,000 | 25,000 | 33,000 | — | — | — | — | — |
| Loans under CARES Act - noncurrent | 0 | 266,000 | 371,000 | 371,000 | 105,000 | 105,000 | 149,000 | — |
| Promissory note to related party | 150,000 | — | — | — | — | — | — | — |
| Total liabilities | 682,000 | 1,271,000 | 1,514,000 | 8,055,000 | 7,627,000 | 7,856,000 | 7,524,000 | 7,309,000 |
| Stockholders' equity (deficit): | ||||||||
| Common stock - $0.01 par value per share; 100,000 shares authorized, 65,093 and 21,650 shares issued and outstanding at December 31, 2021 and 2020, respectively | 651,000 | 651,000 | 651,000 | 221,000 | 216,000 | 216,000 | 216,000 | 216,000 |
| Additional paid-in capital | 389,610,000 | 389,596,000 | 389,581,000 | 383,105,000 | 383,097,000 | 383,088,000 | 383,079,000 | 383,070,000 |
| Accumulated deficit | (390,083,000) | (390,112,000) | (389,850,000) | (389,463,000) | (389,204,000) | (388,961,000) | (388,283,000) | (388,591,000) |
| Total stockholders' equity (deficit) | 178,000 | 135,000 | 382,000 | (6,137,000) | (5,891,000) | (5,657,000) | (4,988,000) | (5,305,000) |
| Total liabilities and stockholders' equity (deficit) | 860,000 | 1,406,000 | 1,896,000 | 1,918,000 | 1,736,000 | 2,199,000 | 2,536,000 | 2,004,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.